Physician

Gary Lu, M.D., PH.D

According to 2025 Medicare claims, Gary Lu, M.D., PH.D (NPI: 1588906457) practices hematology/oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Denton, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76201-4315. Lu is affiliated with the St. Luke's Medicare ACO (ACO ID: A3560) and UT Southwestern Accountable Care Network (ACO ID: D0211), participating under both the MSSP and REACH models.

Lu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 589 traditional Medicare patients, billed 182,408 HCPCS/CPT codes, and received $3,394,228 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,143 prescription claims across 200 beneficiaries totaling $1,474,886 in drug costs, led by Kisqali (Ribociclib Succinate). 2021 DME data shows 48 claims. Open Payments data shows 24 records totaling $18,743. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $22,096 to $3,394,228. Similarly, Part D prescription costs have risen steadily, from $84,811 to $1,474,886. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	124	234	$22,096
2018	559	1,463	$123,341
2019	700	1,800	$157,157
2020	583	1,614	$134,588
2021	537	1,256	$129,352
2022	551	184,243	$2,468,322
2023	499	152,064	$2,692,362
2024	589	182,408	$3,394,228

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	21	83	$84,811
2016	16	57	$129,628
2017	44	113	$182,698
2018	138	674	$1,077,528
2019	194	982	$2,620,161
2020	238	1,372	$3,381,750
2021	240	1,404	$4,173,679
2022	213	821	$1,219,925
2023	161	973	$732,021
2024	200	1,143	$1,474,886

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	11	$207
2019	N/R	N/R	N/R
2020	N/R	50	$3,235
2021	N/R	48	$3,069
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	213	628	$92
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	175	376	$12
80053	Blood test, comprehensive group of blood chemicals	233	778	$10
36415	Insertion of needle into vein for collection of blood sample	249	761	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	239	810	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kisqali	Ribociclib Succinate	12	336	$185,890
Lenalidomide	Lenalidomide	16	427	$140,821
Lynparza	Olaparib	12	349	$98,834
Abiraterone Acetate	Abiraterone Acetate	25	750	$64,085
Eliquis	Apixaban	54	2,160	$40,765

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$1,043	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$17,700	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gary Lu, M.D., PH.D?

Tedicare shows public-source Medicare data for Gary Lu, M.D., PH.D (NPI 1588906457), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gary Lu, M.D., PH.D have ACO affiliation data?

Gary Lu, M.D., PH.D is shown with ACO affiliation data for St. Luke's Medicare ACO (MSSP, ACO ID A3560) and UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Gary Lu, M.D., PH.D?

Gary Lu, M.D., PH.D is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Gary Lu, M.D., PH.D have Open Payments data?

Gary Lu, M.D., PH.D has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.